This trial is evaluating whether Deep Brain Stimulation will improve 5 primary outcomes, 3 secondary outcomes, and 4 other outcomes in patients with Alzheimer Disease. Measurement will happen over the course of Baseline, Post-Operative Months 6, 12.
This trial requires 12 total participants across 1 different treatment group
This trial involves a single treatment. Deep Brain Stimulation is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"There is considerable variation in the efficacy of treatments for AD; the majority of this variability reflects differences in the disease pathology, rather than differences in treatment effect. Data from a recent study imply that the only reasonable expectation for any AD treatment is that it will improve some aspect of cognitive or behavioral deficits in some individuals." - Anonymous Online Contributor
"It is difficult to determine the exact date of onset of AD, but a rapid decline in cognitive function, memory impairment and behavioural changes (such as irritability, mood swings or aggression) are typical signs.\n" - Anonymous Online Contributor
"Antihormones are commonly given to help with dementia because dementia is commonly caused by Alzheimer's disease. Antihormones are not the only treatment but it also helps to control the Alzheimer's disease like in the brain. Neurotransmitters may also have some effect of dementia." - Anonymous Online Contributor
"Factors associated with the development of Alzheimer disease include age, age at onset, gender, family history, cognition, education, and genetics, but these factors do not make up the full picture. The cause may relate to the process of brain aging from normal and normal-aging, or it may be that the process of aging itself results in the development of Alzheimer's disease." - Anonymous Online Contributor
"Currently there are no cure for Alzheimer disease despite several years of intensive research. A disease that destroys such an integral portion of our daily lives can only be treated to an extent. Alzheimer's can cause significant financial hardship and loss for those caring for them. Patients, families, and friends of sufferers can experience great emotional pain while trying to cope under the debilitating disability that is Alzheimer's disease. As we delve into the future of Alzheimer's there are several avenues to explore in order to find treatments that could halt the disease or possibly cure it. There is still a great deal of information to gather before any therapeutic methods or remedies could be implemented. The most reliable method of information acquisition is through trial and error and ongoing research." - Anonymous Online Contributor
"In 2003 and 2004, the combined estimate of cases of Alzheimer disease and related dementias (AD+PD, AD+DP, AD+VF, and ARD) was 394,873, accounting for 2.4% and 2.0% of the population, aged 65 and over, respectively. In 2010, the combined estimate of diagnoses of Alzheimer disease a year was 41,900, accounting for 2.6% of the population 65 and over." - Anonymous Online Contributor
"Of the 3 types of DBS, subperiosteal DBS appears to be most effective and less invasively (without exposing the brain to high-dose radiation) and is associated with higher rates of seizure freedom, with the most common side effects being nausea and dizziness, whereas subcaudal DBS was associated with highest rates of complications. Further investigation is needed to determine the efficacy and incidence of complications in all indications of DBS, including subcaudal DBS." - Anonymous Online Contributor
"This review provides a framework for understanding DBS as a therapeutic agent, incorporating current knowledge of its mechanisms of action. This framework highlights specific brain regions important in DBS as a therapy, and provides useful guidance for practitioners. This review also highlights a number of areas where DBS may be improved, which should be considered as we advance our understanding of the cellular mechanisms of DBS." - Anonymous Online Contributor
"Results from a recent paper of our study suggest that older adults with mild AD may develop complications from minor fractures and major health issues. In contrast, the results of our study suggest that older adults with moderate AD should not be over- or underestimated because they may have a high likelihood of experiencing serious consequences." - Anonymous Online Contributor
"Most patients need additional treatment beyond what they are receiving as part of their care and for the majority of them there would be a likelihood of being cured by clinical trials. Physicians and patients should consider all aspects of the potential benefits and risks before making a decision about clinical trials." - Anonymous Online Contributor
"The current article was derived from a previous abstract that was presented at an FDA meeting. Further clinical trials and meta-analyses will be warranted to establish the efficacy and safety of DBS in treating symptoms such as psychosis, depression or dystonia." - Anonymous Online Contributor
"Results from a recent clinical trial of the present study showed that the DBS of the subcallosal gyrus does not increase the efficacy of antipsychotic drug treatment in patients suffering from drug resistant AD. But it may slightly reduce the severity of motor symptoms in some." - Anonymous Online Contributor